Date: 2015-04-01
Type of information: Company acquisition
Acquired company: UCB's brands in India
Acquiring company: Dr. Reddy’s (India)
Amount: €118 million
Terms: * On April 1, 2015, in line with its strategic focus, UCB announced it has entered an agreement with Dr. Reddy’s to sell its established brands in India, including its franchises in the areas of allergies and respiratory disorders. The amount of the transaction amounts to INR 8000 million (~ €118 million). The agreement includes the transfer of approximately 350 members of staff to Dr. Reddy’s. The revenues of the acquired business is ~ INR 1500 million for calendar year 2014. The agreement is in line with UCB’s strategy to provide the best value for patients and to focus on bringing them innovative drugs while ensuring its mature brands portfolio continues to reach as many people as possible. The acquisition includes market leading brands like Atarax, Nootropil, Zyrtec, Xyzal, Xyzal M. The transaction is expected to be closed in the first quarter of the financial year 2015-16.
Details: The acquisition of UCB’s existing brand equity in the areas of Dermatology, Respiratory and Pediatrics diseases will further expand Dr. Reddy’s therapy footprint into these areas.
Related: Allergic diseases Dermatological diseases Neurological diseases Respiratory diseases
